This study will randomize all patients who are new to the Mayo Clinic HPN team to either standard lipid emulsion (Intralipid) or SMOFLipid.
Full Title of Study: “Randomized Prospective Trial Comparing Intralipid Versus SMOFlipid in New HPN Patients.”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Supportive Care
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: November 30, 2021
Primary aim is to assess the impact to direct bilirubin.
Secondary aims will be to assess impact to other liver function studies, metabolic parameters, inflammatory marker, body weight, ability to meet caloric needs through TPN, and ability to obtain appropriate macronutrient composition.
- Dietary Supplement: SMOFLipid
- SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
- Dietary Supplement: Intralipid
- Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
Arms, Groups and Cohorts
- Active Comparator: SMOFLipid
- SMOFlipid is a lipid emulsion that contains a combination of soybean oil, medium chain triglycerides, olive oil, and fish oil.
- Active Comparator: IntraLipid
- Intralipid is a lipid emulsion that contains soybean oil
Clinical Trial Outcome Measures
- Direct Bilirubin Change is assessed
- Time Frame: At 12 weeks weeks
Participating in This Clinical Trial
- Newly initiated Mayo Clinic HPN patient
- Able to provide informed consent
- Anticipated duration of HPN greater than 3 months,
- Infusion company is able to provide Smoflipid
- Age less than 18 years
- Pregnant and lactating women
- Failure to provide consent
- Patients with underlying liver dysfunction (defined as liver function studies equal to or more than 2 times upper limit of normal) or pathology as determined by primary investigator
- Patients with active malignancy
- Patients who are deemed to be on HPN for less than three months
- Patients who have previous proven addiction and dependence to alcohol/ heavy alcohol AND consumption/active use reported during last 12 months.
- Known hypersensitivity to fish, egg, soybean, or peanut protein, or to any of the active ingredients or excipients in Smoflipid
- Patients who will not be managed by the Mayo Clinic HPN team
- Patients who have active infection (as determined by the clinician) at the time of enrollment.
- Patients who have received Smoflipid greater than 4 weeks in the last 12 months prior to enrollment.
- Patients who have been on TPN greater than 4 weeks in the last 12 months prior to enrollment.
- Enrolled in another interventional study.
- Severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides more than 1,000 mg/dL.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 75 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Mayo Clinic
- Provider of Information About this Clinical Study
- Principal Investigator: Manpreet S. Mundi, Principal Investigator – Mayo Clinic
- Overall Official(s)
- Manpreet S Mundi, MD, Principal Investigator, Mayo Clinic
- Overall Contact(s)
- Manpreet S Mundi, MD, 507-284-4080, Mundi.Manpreet@mayo.edu
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.